EFSA Journal (Dec 2019)

Safety and efficacy of Elancoban® G200 (monensin sodium) for chickens for fattening, chickens reared for laying and turkeys

  • EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP),
  • Vasileios Bampidis,
  • Giovanna Azimonti,
  • Maria de Lourdes Bastos,
  • Henrik Christensen,
  • Birgit Dusemund,
  • Mojca Kos Durjava,
  • Marta López‐Alonso,
  • Secundino López Puente,
  • Francesca Marcon,
  • Baltasar Mayo,
  • Alena Pechová,
  • Mariana Petkova,
  • Fernando Ramos,
  • Yolanda Sanz,
  • Roberto Edoardo Villa,
  • Ruud Woutersen,
  • Georges Bories,
  • Paul Brantom,
  • Jürgen Gropp,
  • Antonio Finizio,
  • Andreas Focks,
  • Ivana Teodorovic,
  • Boet Glandorf,
  • Lieve Herman,
  • Miguel Prieto Maradona,
  • Orsolya Holczknecht,
  • Jordi Tárres‐Call,
  • Maria Vittoria Vettori,
  • Maryline Kouba

DOI
https://doi.org/10.2903/j.efsa.2019.5891
Journal volume & issue
Vol. 17, no. 12
pp. n/a – n/a

Abstract

Read online

Abstract The feed additive Elancoban® G200, containing the active substance monensin sodium, an ionophore anticoccidial, is intended to control coccidiosis in chickens for fattening, chickens reared for laying and turkeys. The FEEDAP Panel cannot conclude on the safety of the additive for the target species, consumer, user and environment with regard to the safety of the production strain. The following conclusions apply to monensin sodium included in the additive. Based on the available data set, the FEEDAP Panel cannot conclude on the safety of Elancoban® G200 for chickens for fattening. Monensin sodium is safe for turkeys for fattening with a margin of safety of 1.5. Monensin sodium is not genotoxic and not carcinogenic. The pharmacological no observed adverse effect level (NOAEL) of 0.345 mg monensin sodium/kg body weight (bw) per day was identified in dog. The acceptable daily intake (ADI) derived from this NOAEL is 0.003 mg monensin sodium/kg bw applying an uncertainty factor of 100. Elancoban® G200 is safe for the consumer. The existing maximum residue limits (MRLs) ensure consumer safety, provided that the withdrawal period of 1 day is respected. Elancoban® G200 is very irritant for the eye, but it is not a skin irritant. Elancoban® G200 should be regarded as a potential skin and respiratory sensitiser. Inhalation exposure is considered a risk to persons handling the additive. Elancoban® G200 does not pose a risk for the terrestrial compartment, the aquatic compartment and the sediment. The bioaccumulation potential of monensin in the environment is low. Monensin sodium from Elancoban® G200 has the potential to effectively control coccidiosis in chickens for fattening and chickens reared for laying. The FEEDAP Panel cannot conclude on the efficacy Elancoban® G200 as a coccidiostat for turkeys for fattening.

Keywords